Henry Schein
✦ Quant Fair Value how this is computed
- Implied fair-value range of 60.08-83.62, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is +16.2% above the average-multiple fair value of 71.85.
Valuation each multiple against its own 5-year range
Vs. peers Medical Distribution
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Henry Schein (HSIC) | 9.23B | 22.88 | 2.92 | 0.00% |
| McKesson (MCK) | 123.47B | 27.48 | -31.23 | 0.32% |
| Cencora (COR) | 64.71B | 18.89 | 17.58 | 0.71% |
| Cardinal Health (CAH) | 63.06B | 35.29 | -20.84 | 0.75% |
| Akso Health (AHG) | 1.08B | -42.00 | 5.97 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 8.6% above Morningstar's fair value estimate.
Fair value
Henry Schein Inc is assigned a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 13% premium over our quantitative fair value estimate of $76.32 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.
The firm's unfavorable dividend structure undermines our estimated valuation. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. Reflecting the firm's dividends is its forward dividend yield of 0%, which sits in the bottom 30% globally. This could imply a planned dividend cut or relatively high share price, which contributes to our view that shares are expensive.
The company's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 33.2%, a core component of valuation, falls in the bottom 30% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our unfavorable price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
Economic moat
The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
By Quantitative Equity Report
Quote time 2026-11-20 20:01:08 · For reference only, not investment advice and not tailored to your situation.
Henry Schein discussion 0 comments